GU Cancer ESMO 2023 Highlights

EP. 1: SunRISe-1: Updated Data With TAR-200 Monotherapy in NMIBC

ByRohit Gosain, MD,Rahul Gosain, MD,Rana R. McKay, MD

November 7th 2023

Key opinion leader Rana McKay, MD, joins the Oncology Brothers Rahul Gosain, MD, and Rohit Gosain, MD, to review updated data in GU cancer from ESMO 2023, starting with TAR-200 monotherapy in patients with NMIBC and the SunRISE-1 trial.

EP. 2: EV-302: Impact of Enfortumab Vedotin + Pembrolizumab in Metastatic Bladder Cancer

ByRohit Gosain, MD,Rahul Gosain, MD,Rana R. McKay, MD

November 7th 2023

Shifting their focus to metastatic bladder cancer, the Oncology Brothers and Rana McKay, MD, reflect on data from EV-302 and consider how enfortumab vedotin + pembrolizumab has shifted the treatment landscape.

EP. 3: PSMAfore: Lutetium-177–PSMA-617 in Metastatic CRPC

ByRohit Gosain, MD,Rahul Gosain, MD,Rana R. McKay, MD

November 7th 2023

Shared insight from Rana McKay, MD, and the Oncology Brothers on updated data from PSMAfore and the use of Lutetium-177–PSMA-617 in patients with metastatic castration-resistant prostate cancer.

EP. 4: Closing Thoughts on GU Cancer Updates from ESMO 2023

ByRohit Gosain, MD,Rahul Gosain, MD,Rana R. McKay, MD

November 7th 2023

Following their program on data updates in GU cancer from ESMO 2023, Oncology Brothers Rahul Gosain, MD, and Rohit Gosain, MD, share key takeaways from SunRISe-1, EV-302, and PSMAfore.